NVO
Novo Nordisk A/SNYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
10.28
PEG
1.35
P/B
5.42
P/S
3.41
EV/EBITDA
7.20
DCF Value
$76.84
FCF Yield
5.3%
Div Yield
5.0%
Margins & Returns
Gross Margin
81.0%
Operating Margin
41.3%
Net Margin
33.1%
ROE
61.1%
ROA
24.8%
ROIC
29.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $78.43B | $26.65B | $6.04 |
| FY 2025 | $297.20B | $98.50B | $23.03 |
| Q3 2025 | $74.98B | $20.01B | $4.50 |
| Q2 2025 | $76.86B | $26.50B | $5.96 |
Analyst Ratings
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
DK
Exchange
NYSE
Beta
0.27
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.